Oncogenicity of purine 3-oxide and unsubstituted purine in rats.
Injection s.c. of purine 3-oxide into Wistar rats resulted in the appearance of sarcomas and fibromas at the interscapular site of administration, carcinomas in the liver, and a high incidence of s.c. fibromas in the hip at a distance from the site of injection. A small number of liver tumors but not tumors at the injection site appeared in rats to which the parent compound, purine, was administered. Oxidation of purine 3-oxide by xanthine oxidase was found to occur in two steps to yield the potent oncogen 3-hydroxyxanthine. A similar process may occur in vivo since a protein preparation from rat s.c. tissue has similar oxidizing activity.
D000818:Animals; D002273:Carcinogens; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced; D003238:Connective Tissue / Q000378:metabolism; D003497:Cyclic N-Oxides / Q000633:toxicity; D005350:Fibroma / Q000139:chemically induced; D007042:Hypoxanthines / Q000378:metabolism; D007279:Injections, Subcutaneous; D008113:Liver Neoplasms / Q000139:chemically induced; D008297:Male; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D011687:Purines / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D051381:Rats; D012983:Soft Tissue Neoplasms / Q000139:chemically induced; D014969:Xanthine Oxidase / Q000378:metabolism
D002273:Carcinogens; D003497:Cyclic N-Oxides; D007042:Hypoxanthines; D011687:Purines; C009111:purine N-oxide; D014969:Xanthine Oxidase